SBC Medical Group Holdings Inc financial statements
Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data SBC Medical Group Holdings Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2024
FY2025
Revenue
194
205
174
Cost of revenue
56.2
49.4
46.3
Gross profit
137
156
127
Selling, general and administrative
66.2
57.7
59.8
Operating expenses
66.6
85.7
59.8
Operating income
70.7
70.3
67.5
Interest expense
0.05
0.03
0.15
Interest income
0.09
0.02
0.2
Other non-operating income
2.92
3.15
14.6
Pre-tax income
73.6
73.5
82.1
Income tax
35
26.8
31
Net income to minority interests
-0.81
0.08
0.06
Net income
39.4
46.6
51
EBITDA
82.9
74.1
70.2
EPS, basic
0.42
0.48
0.50
EPS, diluted
0.42
0.48
0.50
Shares, basic (weighted)
94.2
96.6
103
Shares, diluted (weighted)
94.2
96.6
103
Balance sheet
FY2023
FY2024
FY2025
Cash and equivalents
103
125
164
Short-term investments
0
0.32
Inventory
3.09
1.49
2.79
Other current assets
0.16
0.03
0.13
Total current assets
166
184
231
Property, plant and equipment
13.6
8.77
7.54
Lease right-of-use assets
5.92
5.27
8.37
Goodwill
3.59
4.61
15.4
Intangible assets
19.7
1.59
47.7
Long-term investments
0.85
3.05
1.3
Other non-current assets
15.4
15.6
7.26
Total assets
259
266
380
Accounts payable
26.5
Accrued liabilities
0.48
Short-term debt
0.33
0.26
0.23
Total current liabilities
92.5
61.2
61.1
Long-term debt
11.9
0.01
0
Lease liabilities
2.44
1.24
4.14
Other non-current liabilities
1.07
1.19
1.66
Total liabilities
115
71.1
117
Total debt
6.6
42.8
Paid-in capital
36.9
62.5
72.9
Retained earnings
143
189
240
Treasury stock
-2.7
-7.75
Other comprehensive income
-37.6
-54.2
-57.3
Shareholders' equity
142
195
248
Minority interests
1.65
-0.09
15
Total equity
144
195
263
Total liabilities and equity
259
266
380
Shares outstanding
94.2
103
103
Cash flow statement
FY2023
FY2024
FY2025
Net income
38.6
46.7
51
Depreciation and amortization
12.2
3.8
2.68
Stock-based compensation
13
0
Deferred income tax
4.11
-14.4
5.33
Change in inventory
-1.83
1.12
-0.17
Change in payables
-0.04
Cash from operations
50.7
20.6
24.7
Capital expenditures
-8.54
-2.56
-1.4
Purchases of investments
-2.11
0
-20.1
Cash from investing
1.79
-10.1
-21
Stock issued
0
Share buybacks
0
-5
Cash from financing
6.14
23
38.3
Net change in cash
51.3
22
38.7
Free cash flow
42.1
18
23.3
Interest paid
0.05
0.03
0.16
Income taxes paid
17.8
30.2
37.2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.90 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
71.9%
Gross profit / revenue.
Operating margin
37.3%
Operating income / revenue.
EBITDA margin
38.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
43.1%
Pre-tax income / revenue.
Net margin
28.0%
Net income / revenue.
FCF margin
35.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
35.9%
Cash from operations / revenue.
Effective tax rate
33.5%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
18.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
12.1%
Net income / average total assets.
Return on invested capital (ROIC)
37.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
SG&A / revenue
34.5%
Selling, general and administrative expense / revenue.
Capex / revenue
0.6%
Capital expenditures / revenue.
D&A / revenue
1.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-15.5%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
-18.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Operating income growth, 1y
-4.0%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-5.3%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
9.4%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
4.2%
EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
19.8%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
29.1%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
27.3%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
43.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
6.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.31x
Current assets / current liabilities.
Quick ratio
2.35x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.35x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.14x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
9.3%
Total debt / total assets.
Liabilities / assets
31.2%
Total liabilities / total assets.
Net debt
-$146.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
-2.17x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Free cash flow / net income, when net income is positive.
Capex / operating cash flow
1.7%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.48
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.71
Revenue / diluted weighted shares.
FCF per share
$0.60
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.61
Cash from operations / diluted weighted shares.
Book value per share
$2.57
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
10.3x
Market cap / net income. Only when net income is positive.
P/S
2.88x
Market cap / revenue.
P/B
1.91x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.48x
Market cap / tangible book value, when positive.
P/FCF
8.16x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
8.02x
Market cap / cash from operations, when positive.
EV/Sales
2.04x
Enterprise value / revenue.
EV/EBIT
5.46x
Enterprise value / operating income, when both are positive.
EV/EBITDA
5.28x
Enterprise value / EBITDA, when both are positive.
EV/FCF
5.78x
Enterprise value / free cash flow, when both are positive.
FCF yield
12.3%
Free cash flow / market cap.
Earnings yield
9.7%
Net income / market cap (the inverse of P/E).
What was SBC Medical Group Holdings Inc's revenue in fiscal 2025?
SBC Medical Group Holdings Inc reported revenue of $173.6M for fiscal 2025, 15.5% lower than the year before.
Was SBC Medical Group Holdings Inc profitable in fiscal 2025?
Yes. Net income was $51.0M, a net margin of 29.4%.
How much free cash flow did SBC Medical Group Holdings Inc generate in fiscal 2025?
Cash from operations of $24.7M minus capital expenditures of $1.4M left free cash flow of $23.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.